KINIKSA PHARMACEUTICALS LTD

NASDAQ: KNSA (Kiniksa Pharmaceuticals, Ltd.)

Last update: 3 days ago, 11:09AM

40.29

1.36 (3.49%)

  • 1D 3.49%
  • 5D 3.92%
  • 1M 3.76%
  • 6M 49.39%
  • YTD 102.06%
  • 1Y 75.10%
  • 5Y 157.28%
Previous Close 38.93
Open 39.65
Volume 220,520
Avg. Volume (3M) 510,837
Market Cap 2,985,797,888
Price / Earnings (TTM) 805.80
Price / Sales 5.27
Price / Book 5.61
52 Weeks Range
17.82 (-55%) — 40.89 (1%)
Earnings Date 28 Oct 2025
Profit Margin -3.52%
Operating Margin (TTM) 9.63%
Diluted EPS (TTM) -0.240
Quarterly Revenue Growth (YOY) 72.50%
Total Debt/Equity (MRQ) 2.17%
Current Ratio (MRQ) 3.66
Operating Cash Flow (TTM) 44.03 M
Levered Free Cash Flow (TTM) 25.15 M
Return on Assets (TTM) -1.77%
Return on Equity (TTM) -3.81%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bullish Bullish
Stock Kiniksa Pharmaceuticals, Ltd. Bearish Bullish

AIStockmoo Score

-0.5
Analyst Consensus 1.0
Insider Activity -5.0
Price Volatility -3.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average -0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
KNSA 3 B - 805.80 5.61
LNTH 5 B - 20.97 3.07
ALVO 3 B - 35.78 -
BCRX 2 B - - 56.59
HROW 1 B - - 35.57
ETON 514 M - - 22.16

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Growth
% Held by Insiders 3.80%
% Held by Institutions 97.31%
52 Weeks Range
17.82 (-55%) — 40.89 (1%)
Price Target Range
44.00 (9%) — 60.00 (48%)
High 60.00 (TD Cowen, 48.92%) Buy
Median 50.00 (24.10%)
Low 44.00 (Wedbush, 9.21%) Buy
Average 50.80 (26.09%)
Total 5 Buy
Avg. Price @ Call 37.47
Firm Date Target Price Call Price @ Call
Goldman Sachs 29 Oct 2025 55.00 (36.51%) Buy 37.38
Citigroup 17 Oct 2025 50.00 (24.10%) Buy 38.64
Wedbush 13 Oct 2025 44.00 (9.21%) Buy 37.03
TD Cowen 29 Sep 2025 60.00 (48.92%) Buy 38.77
Wells Fargo 25 Sep 2025 45.00 (11.69%) Buy 35.51
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
MEGNA MICHAEL R - 38.99 -50,490 -1,968,605
PATEL SANJ K - 38.91 -257,969 -10,043,940
Aggregate Net Quantity -308,459
Aggregate Net Value ($) -12,012,545
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 38.93
Name Holder Date Type Quantity Price Value ($)
PATEL SANJ K Officer 22 Oct 2025 Automatic sell (-) 97,390 38.90 3,788,471
PATEL SANJ K Officer 22 Oct 2025 Option execute 97,390 - -
PATEL SANJ K Officer 21 Oct 2025 Automatic sell (-) 39,331 38.85 1,528,009
PATEL SANJ K Officer 21 Oct 2025 Option execute 39,331 - -
MEGNA MICHAEL R Officer 20 Oct 2025 Automatic sell (-) 50,490 38.99 1,968,605
MEGNA MICHAEL R Officer 20 Oct 2025 Option execute 39,435 - -
PATEL SANJ K Officer 20 Oct 2025 Automatic sell (-) 121,248 38.99 4,727,460
PATEL SANJ K Officer 20 Oct 2025 Option execute 121,248 - -

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria